<DOC>
	<DOCNO>NCT00063232</DOCNO>
	<brief_summary>Nonalcoholic Steatohepatitis ( NASH ) associate progressive liver disease , fibrosis , cirrhosis . Although cause NASH unknown , often associate obesity , type 2 diabetes , insulin resistance . At present , approve treatment NASH patient , experimental approach focus improve insulin sensitivity . Metformin one commonly used medication treatment diabetes . The purpose study determine whether medical problem NASH patient , specifically liver damage , improve insulin sensitivity enhance metformin . The study last 3 5 year enroll 30 patient . Participants undergo complete medical examination , series lab test , liver biopsy . They start take single 500-mg tablet metformin day 2 week , dosage twice day 2 week , tolerate first dosage . The dosage increase 1,000 mg twice day remain 44 week study . After 1 year , participant undergo repeat medical examination liver biopsy .</brief_summary>
	<brief_title>Treating Nonalcoholic Steatohepatitis ( NASH ) With Metformin</brief_title>
	<detailed_description>Nonalcoholic fatty liver disease ( NAFLD ) represent spectrum disease range simple fatty liver ( steatosis ) steatosis inflammation necrosis cirrhosis , occur person drink little alcohol . Nonalcoholic steatohepatitis ( NASH ) represent severe end spectrum associate progressive liver disease , fibrosis cirrhosis . The etiology NASH unclear , often associate obesity , type 2 diabetes , hyperlipidemia insulin resistance . We recently conduct study 48-week course pioglitazone 21 non-diabetic patient NASH . Serum aminotransferase level liver histology improved patient improvement correlate change insulin sensitivity . These result promising , pioglitazone associate significant weight gain , quite expensive , long-term safety yet prove . In contrast , metformin inexpensive , extremely well tolerate , proven long-term safety patient diabetes pre-diabetes . In study , propose treat 20 non-diabetic patient NASH metformin 48-weeks . After initial evaluation insulin sensitivity , fat distribution liver biopsy , patient receive gradually increase dos metformin orally maximum 2000 mg daily . Patients monitor regular interval symptoms liver disease , side effect metformin serum biochemical metabolic index . At end 48-weeks , patient repeat medical evaluation liver biopsy . Pre post treatment liver histology , fat distribution insulin sensitivity compare . The primary end point successful therapy improvement hepatic histology determine reduction least three point NASH activity score . Secondary end point improvement insulin sensitivity , body fat distribution , liver biochemistry .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Age entry least 18 year . 2 . Serum alanine ( ALT ) aspartate ( AST ) aminotransferase activity upper limit normal . 3 . Evidence steatohepatitis liver biopsy do within previous 12 month NASH activity score least 4 ( total possible score 16 ) include score least 1 steatosis , hepatocellular injury parenchymal inflammation . Histological criterion steatohepatitis include : ( 1 ) macrovesicular steatosis , ( 2 ) acinar zone 3 hepatocellular injury ( balloon degeneration ) , ( 3 ) parenchymal ( 4 ) portal inflammation . Additionally helpful , require , feature include presence ( 5 ) Mallory 's hyaline ( 6 ) pericellular and/or sinusoidal fibrosis predominantly involve zone 3 . 4 . Written informed consent . EXCLUSION CRITERIA : 1 . Evidence another form liver disease . 1 . Hepatitis B define presence hepatitis B surface antigen ( HBsAg ) . 2 . Hepatitis C define presence hepatitis C virus ( HCV ) RNA serum . 3 . Autoimmune hepatitis define antinuclear antibody ( ANA ) 1:160 great liver histology consistent autoimmune hepatitis previous response immunosuppressive therapy . 4 . Autoimmune cholestatic liver disorder define elevation alkaline phosphatase antimitochondrial antibody great 1:80 liver histology consistent primary biliary cirrhosis elevation alkaline phosphatase liver histology consistent sclerosing cholangitis . 5 . Wilson disease define ceruloplasmin limit normal liver histology consistent Wilson disease . 6 . Alpha1antitrypsin deficiency define alpha1antitrypsin level less normal liver histology consistent alpha1antitrypsin deficiency . 7 . Hemochromatosis define presence 3+ 4+ stainable iron liver biopsy homozygosity C282Y compound heterozygosity C282Y/H63D . 8 . Druginduced liver disease define basis typical exposure history . 9 . Bile duct obstruction show imaging study . 2 . History excess alcohol ingestion , average 30 gm/day ( 3 drink per day ) previous 10 year , history alcohol intake average great 10 gm/day ( 1drink per day : 7 drink per week ) previous one year . 3 . Contraindications liver biopsy : platelet count less 75,000/mm ( 3 ) prothrombin time great 16 second . 4 . Decompensated liver disease , ChildPugh score great equal 7 point . 5 . History gastrointestinal bypass surgery ingestion drug know produce hepatic steatosis include corticosteroid , highdose estrogen , methotrexate , tetracycline amiodarone previous 6 month . 6 . Presence diabetes mellitus define : fasting plasma glucose great equal 126 mg/dl two separate occasion , diabetic symptom random plasma glucose great equal 200 mg/dl ( 34 ) . 7 . Use antidiabetic drug , include insulin , biguanides , sulfonylurea , thiazolidinediones previous 6 month . 8 . Significant systemic major illness liver disease , include congestive heart failure , coronary artery disease , cerebrovascular disease , pulmonary disease hypoxia , renal failure , organ transplantation , serious psychiatric disease , malignancy , opinion investigator would preclude treatment metformin adequate follow . 9 . Positive test antiHIV . 10 . Active substance abuse , alcohol , inhale injection drug within previous one year . 11 . Pregnancy inability practice adequate contraception woman childbearing potential . 12 . Evidence hepatocellular carcinoma : alphafetoprotein level great 200 ng/ml and/or liver mass image study suggestive liver cancer . 13 . Any condition , , opinion investigator would impede competence compliance possibly hinder completion study . 14 . History hypersensitivity reaction metformin . 15 . Serum creatinine great 1.5 mg/dl men great 1.4 mg/dl woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Insulin</keyword>
	<keyword>Obesity</keyword>
	<keyword>Fatty Liver</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Metformin</keyword>
	<keyword>Insulin Resistance</keyword>
	<keyword>Nonalcoholic Steatohepatitis</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>NASH</keyword>
</DOC>